DocWire News Editors

DocwireNews

A multi-center, international trial found that type 2 diabetes (T2D) medications linagliptin and glimepiride have similar safety profiles among patients at high-risk for cardiovascular outcomes. The findings were presented at the American Diabetes Association&rsquo;s (ADA&rsquo;s) 79th Scientific Sessions in San Francisco.The CAROLINA trial took place between 2010 and 2018 and included 6,033 T2D patients (age range, 40 to 85 years; median disease duration, 6.2 years) from more than 600 sites in 43 countries. All patients had established cardiovascular disease (CVD) or had a high risk of CVD. Patients were randomized to receive, in addition to their usual treatment, a 5 mg daily dose of linagliptin or a daily dose of up to 4 mg of glimepiride. The primary outcome was a composite of cardiovascular (CV) death, non-fatal myocardial infarction, or non-fatal stroke.The analysis included 3,020 patients taking linagliptin and 3,010 taking glimepiride. After a median follow-up of 6.3 years, the hazard ratio (HR) for the primary outcome between the linagliptin and glimepiride groups was 0.98; the HRs for CV mortality and non-CV mortality were 1.00 and 0.82, respectively. HbA1c did not significantly differ between the two groups.&nbsp; In the linagliptin group, 10.6% of patients experienced at least one hypoglycemia episode, compared to 37.7% in the glimepiride group. Weight differed between the groups, with the linagliptin cohort weighing an average 1.5 kg less than the glimepiride group.The results&mdash;that CV outcomes did not differ between the two groups&mdash;surprised the researchers, according to Julio Rosenstock, MD, trial principal investigator and director of the Dallas Diabetes Research Center at Medical City and clinical professor of medicine at the University of Texas Southwestern Medical Center in Dallas, Texas.&ldquo;However, with a significantly higher risk of hypoglycemia and a modest, but statistically significant, weight gain with glimepiride compared with linagliptin, results from the CAROLINA trial confirm an important, clinically-relevant safety advantage of linagliptin over glimepiride that should be considered in the decision-making process for selecting therapy in addition to cost considerations,&rdquo; Dr. Rosenstock said in a press release.

Jordana Jampel

Cutaneous Melanoma: Sun Protection Behaviors and UV Exposure in Canada

Melanoma

Leah Lawrence

Significant Cardiac Benefit Seen With Ifetroban in Patients With Duchenne Muscular Dystrophy

Neurology

Apitegromab Improved Motor Function in Type 2/3 Spinal Muscular Atrophy

Latest News

No Significant Differences in CV Outcomes for Linagliptin and Glimepiride

American Diabetes Association Scientific Sessions 2019

A multi-center, international trial found that type 2 diabetes (T2D) medications linagliptin and glimepiride have similar safety profiles among patients at high-risk for ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe